| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Propanamide, N-cyclohexyl-2,2-dimethyl-N-[6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]hexyl]- manufacturers
- IHVR-17028
-
- $178.00
-
2026-08-30
- CAS:1428247-78-2
- Purity: 99.33%
- Supply Ability: 10g
|
| | Propanamide, N-cyclohexyl-2,2-dimethyl-N-[6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]hexyl]- Basic information |
| Product Name: | Propanamide, N-cyclohexyl-2,2-dimethyl-N-[6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]hexyl]- | | Synonyms: | Propanamide, N-cyclohexyl-2,2-dimethyl-N-[6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]hexyl]-;IHVR-17028;IHVR-17028, 10 mM in DMSO | | CAS: | 1428247-78-2 | | MF: | C23H44N2O5 | | MW: | 428.61 | | EINECS: | | | Product Categories: | | | Mol File: | 1428247-78-2.mol | ![Propanamide, N-cyclohexyl-2,2-dimethyl-N-[6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]hexyl]- Structure](CAS/20210305/GIF/1428247-78-2.gif) |
| | Propanamide, N-cyclohexyl-2,2-dimethyl-N-[6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]hexyl]- Chemical Properties |
| Boiling point | 617.2±55.0 °C(Predicted) | | density | 1.15±0.1 g/cm3(Predicted) | | pka | 13.72±0.70(Predicted) | | form | Oil | | color | Colorless to light yellow |
| | Propanamide, N-cyclohexyl-2,2-dimethyl-N-[6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]hexyl]- Usage And Synthesis |
| Uses | IHVR-17028 is a potent and broad-spectrum antiviral agent. IHVR-17028 exhibits antiviral activity against BVDV, TCRV and DENV with EC50 values of 0.4 μM, 0.26 μM, 0.3 μM, respectively. IHVR-17028 is a potent ER α-glucosidaseIinhibitor with an IC50 of 0.24 μM. IHVR-17028 can be used for infectious diseases research[1][2]. | | in vivo | In Pharmacokinetic analysis in rats, IHVR17028 (oral gavage; 75 mg/kg) shows a Cmaxvalue of 0.18 μg/ml; the Tmax value is 1.56 hours; and the F% value is 12% after PO administration, the T1/2 value is 0.88 hour after iv. adminstration[1].IHVR-17028 (oral gavage; 25-50 mg/kg; treatment 1 day prior to virus challenging) exhibits significant protection in mouse model of lethal MARV infection[1]. | Animal Model: | BALB/c mice are challenged with 1,000 PFU mouse adapted MARV via IP injection[1] | | Dosage: | 50 mg/kg | | Administration: | Treatment 1 day prior to virus challenging | | Result: | Exhibited protection in mouse when the treatment is initiated 1 day prior to virus challenging. |
| Animal Model: | C57B1/6 mice challenged with 1,000 PFU mouse adapted EBOV[1] | | Dosage: | 25 mg/kg | | Administration: | Twice daily at 12 h interval; starting 4 h post infection for 10 days | | Result: | Inhibited EBOV infection in mice. |
| | References | [1] Jinhong Chang, et al. Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses.Antiviral Res. 2013 Jun;98(3):432-40. DOI:10.1016/j.antiviral.2013.03.023 |
| | Propanamide, N-cyclohexyl-2,2-dimethyl-N-[6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]hexyl]- Preparation Products And Raw materials |
|